Petros Grivas MD, PhD
Professor, Department of Medicine, Division of Medical Oncology; Clinical Director, Genitourinary Cancers Program, University of Washington; Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WashingtonDr. Petros Grivas has published widely in highly esteemed peer-reviewed journals and has authored more than 240 articles and book chapters. He has been a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), ECOG-ACRIN, ESMO, International Bladder Cancer Network, Bladder Cancer Advocacy Network, among other prestigious professional organizations.
With a strong interest in designing and conducting innovative clinical trials, Dr. Grivas's professional interests also involve clinical and translational research on experimental therapeutics in genitourinary cancers via a molecular biology–based approach aiming to translate results into clinical trials. He is dedicated to exceptional patient care, leadership, mentoring/teaching trainees, community outreach, diversity, equity and inclusion.
Having received his medical degree and PhD in medical oncology from the University of Patras School of Medicine in Greece, Dr. Grivas came to the US for his internal medicine residency at Drexel University College of Medicine/Hahnemann University Hospital in Philadelphia. He completed a fellowship in hematology/oncology at the University of Michigan in 2013 and took part in the GME Scholars Health Care Administration and Leadership Program at Michigan between 2012 and 2014.
Disclosures
Consulting: Aadi Bioscience, AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, CG Oncology Inc., Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, MSD, Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, UroGen. His institution has received grants from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, MSD, Mirati Therapeutics, Pfizer, QED Therapeutics.
Recent Contributions to PracticeUpdate:
- Mutational Load, cDNA and Their Implications for Urothelial Cancer Treatment: ESMO 2017
- Critical Trial Update in Urothelial Carcinoma From ESMO 2017
- New Data on Immunotherapy for Bladder Cancer: Part 1
- Predictive Factors for Immunotherapy in Bladder Cancer: Part 2
- Second Line Pembrolizumab vs Chemotherapy in Bladder Cancer: Insights From ASCO 2017
- Molecular Analysis of Bladder Cancer From ASCO 2017: Clinical Implications
- Updates in Bladder Cancer: New Treatments and Better Genomic Analyses
- Bladder Cancer Highlights From ASCO GU 2017: Clinical Implications
- Chemoradiation in Bladder Cancer: A Review From ASCO GU 2017
- The Role of Molecular Markers in Bladder Cancer From ASCO GU 2017